Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma

Published:2009 Issue: Volume: Page:NA-NA
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jonasch Eric,Corn Paul,Pagliaro Lance C.,Warneke Carla L.,Johnson Marcella M.,Tamboli Pheroze,Ng Chaan,Aparicio Ana,Ashe Robynne G.,Wright John J.,Tannir Nizar M.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24685/fullpdf

Reference33 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin.,2008

2. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma;Motzer;J Clin Oncol.,2002

3. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med.,2007

4. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma;McDermott;J Clin Oncol.,2005

5. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer;Pyrhonen;J Clin Oncol.,1999

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDG PET/CT in the Diagnosis and After Sunitinib Follow-up of Synchronous Base of Tongue and Thyroid Metastases From Renal Cell Carcinoma;Clinical Nuclear Medicine;2024-05

2. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis;Cochrane Database of Systematic Reviews;2023-05-04

3. Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study;JCO Precision Oncology;2023-02

4. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline;Journal of Clinical Oncology;2022-09-01

5. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer;Frontiers in Molecular Biosciences;2022-03-14